Feb. 12 at 5:12 PM
$PDSB Maybe the KOLs who were pointing out the difference between HPV16+ and HPV- H&N Cancer should buy a few shares. MRUS was taken out at a high price despite this argument We languish. We need info about the Phase 3 study. Enrollment? FDA response to request for PFS as an endpoint?
Do we once again need to wait till ASCO for more clarity?
How about the universal flu vaccine in the wake of the FDA declining to consider MRNA’s product?
All we get is patent news.
Frank your life’s work is sitting with a market cap of
$35M while your intention was to revolutionize cancer treatment.
I feel like our next significant press release will either be our death or our ticket to greatness.
Long but tired.
